Redeye provides its first take on Oncopeptides' Q2 report 2026. Sales grew 23% versus Q1 2026. Operating costs amounted to SEK-79m, with an EBIT of SEK-49m. The topline was above our expectations, which is important, though EBIT below due to higher OPEX, which overall suggests a positive share reaction when the market opens.
LÄS MER
